CytoMed Therapeutics (GDTC) Research & Development (2022 - 2025)

CytoMed Therapeutics has disclosed Research & Development across 4 years of filings, most recently posting $283559.0 for Q2 2025.

• In Q2 2025, Research & Development rose 18.25% year-over-year to $283559.0; the TTM figure through Jun 2025 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was -$2.2 million, down 16.13% from the prior year.
• Research & Development came in at $283559.0 for Q2 2025 at CytoMed Therapeutics, up from $239805.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $811319.0 in Q2 2023 to a low of $239805.0 in Q2 2024.
• Average Research & Development over 4 years is $484681.5, with a median of $443801.0 recorded in 2022.
• Year-over-year, Research & Development soared 34.31% in 2023 and slumped 70.44% in 2024.
• Over 4 years, Research & Development stood at $604043.0 in 2022, then surged by 34.31% to $811319.0 in 2023, then tumbled by 70.44% to $239805.0 in 2024, then climbed by 18.25% to $283559.0 in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $283559.0 in Q2 2025, $239805.0 in Q2 2024, and $811319.0 in Q2 2023.